Connor, Clark & Lunn Investment Management Ltd. Vericel Corp Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$31.69 - $39.25 $361,836 - $448,156	-11,418 Reduced 60.98%	7,305 $244,000
Q2 2023 Aug 10, 2023	BUY	$29.0 - $38.37 $252,561 - $334,164	8,709 Added 86.97%	18,723 $703,000
Q1 2023 May 09, 2023	BUY	$23.85 - $31.34 $238,833 - $313,838	10,014 New	10,014 $293,000
Q3 2021 Nov 12, 2021	SELL	$46.35 - $59.75 $496,362 - $639,862	-10,709 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$47.2 - $67.81 $505,464 - $726,177	10,709 New	10,709 $562,000
Q1 2019 May 08, 2019	SELL	$16.23 - $20.29 $487,305 - $609,207	-30,025 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$10.77 - $18.44 $52,234 - $89,434	-4,850 Reduced 13.91%	30,025 $522,000
Q3 2018 Nov 13, 2018	BUY	$9.1 - $14.8 $208,845 - $339,660	22,950 Added 192.45%	34,875 $493,000
Q2 2018 Aug 02, 2018	BUY	$9.6 - $14.6 $114,480 - $174,105	11,925 New	11,925 $116,000

Others Institutions Holding VCEL

# of Institutions

285

Shares Held

49.3M

Call Options Held

91.8K

Put Options Held

23.2K

View Full List

About Vericel Corp

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.92B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

More about VCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account